Despite known advantages of immobilized enzymes, their broad application in pharmaceutical drug manufacturing has not yet caught up. Limited access to commercially available immobilized enzymes on one side and time – and cost – consuming development of new processes on the other side have hampered their broader implementation so far. Herein, we present a walk-away high throughput workflow with state of the art robotic equipment that enables the rapid optimization and development of immobilized enzymes – ready to be scaled - and thus matching the need for speed in modern drug development. Following this workflow, we were able to identify an engineered ketoreductase which was >2-fold more active than the wildtype from L. kefir. Further optimization of the reaction and immobilization conditions lead to an additional 29-fold productivity increase from 0.36 to 10.6 gproduct genzyme−1 for the selected enzyme variant.